SITE004-0144

SITE004 (DEU) › SITE004-0144

SITE004-0144

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-02-20

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 114); relationship: RELATED

severe assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 75); relationship: not assessed

moderate assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 70); relationship: NOT RELATED

mild assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-10-21 (study day 56); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.